Advisory panel members

Disclosures: FK declares that he has no competing interests.

Disclosures: JAF receives salary support from the Epilepsy Foundation and from Epilepsy Study Consortium for consulting work and/or attending Scientific Advisory Boards for Acadia Pharmaceuticals, Acuta Capital Partners, Agrithera, Inc., Alterity Therapeutics Limited, Angelini Pharma S.p.A, Autifony Therapeutics Limited, Axonis Therapeutics, Baergic Bio, Beacon Biosignals, Inc., Biogen, Biohaven Pharmaceuticals, Bloom Science Inc., Bright Minds Biosciences, Inc., Camp4 Therapeutics Corporation, Cerebral Therapeutics, Cerecin Inc., Cerevel, Cognizance Biomarkers, Cowen and Company, LLC, Crossject, Eisai, Encoded Therapeutics, Engrail, Epalex, Epitel Inc, Equilibre BioPharmaceuticals, Genentech, Inc., Grin Therapeutics, IQVIA RDS Inc, iQure Pharma Inc., Janssen Pharmaceutica, Jazz Pharmaceuticals, Korro Bio Inc., Leal Therapeutics Inc, Lipocine, LivaNova, Longboard Pharmaceuticals, Marinus, Modulight.bio, Neumirna Therapeutics, Neurocrine, Neuronetics Inc., NeuroPace, Inc., NeuroPro Therapeutics, Neuroventis, Ono Pharmaceutical Co., Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Paladin Labs Inc., Praxis, PureTech LTY Inc., Rapport Therapeutics, Inc., Receptor Holdings Inc., Sage Therapeutics, Inc., SK Life Sciences, Stoke, Supernus, Takeda, Third Rock Ventures LLC, UCB Inc., Ventus Therapeutics, Vida Ventures Management, Xenon. JAF has also received research support from the Epilepsy Study Consortium (Funded by Eisai and UCB,) Epilepsy Study Consortium/Epilepsy Foundation (Funded by UCB), GW/FACES/One8Foundation and NINDS. JAF is on the editorial board of Lancet Neurology and Neurology Today. She is Chief Medical/Innovation Officer for the Epilepsy Foundation. She is the President and on the Board of Directors for the Epilepsy Study Consortium, Inc. JAF has received travel/meal reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Angelini Pharma S.p.A., Biohaven Pharmaceuticals, Cerebral Therapeutics, Cowen and Company, LLC, Longboard, Neurelis, Neurocrine, NeuroPace Inc., Praxis, Rapport, SK Life Science, Stoke, Takeda, Xenon.

Disclosures: TS declares that he has no competing interests.

Disclosures: BE has received clinical research funds to the University from Abbvie, Anaptys-Bio, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte, Leo, Lilly, Novartis, Pfizer, and UCB. BE has received honorarium for consulting from Amgen, Arcutis, Boehringer-Ingelheim, Bristol Myers Squibb, Janssen, Leo, Ortho, Novartis, Pfizer, and UCB.

Disclosures: LP declares that his institution is a research site for pharmaceutical studies for the following: Novo Nordisk, Dompé, Imcyse, ProVention Bio/Sanofi.

Disclosures: LRL declares that he has no competing interests.

Disclosures: BDC declares that he has received honoraria and reimbursement for serving as a consultant and/or speaker for the following companies: AbbVie, Salix, QOL Medical, AstraZeneca, Ardelyx, Regeneron, Sanofi, and Phathom.

Disclosures: EEA declares that she has no competing interests.

Disclosures: MJM declares that he has no competing interests.

Disclosures: CGB declares that she has no competing interests.

Disclosures: Over the past 3 years, EAS has received grants for her institution from the Eunice Kennedy Shriver Institute of Child Health and Human Development of the National Institutes of Health (P50HD115283, R01HD105714 and R01HD109127-01A1); has received consulting fees from AbbVie, Anylyn and ASKA; support for service on a DSMB from Myovant (Now Sumitomo Pharma) and travel funding from Aska Pharmaceuticals to attend the Japan Society of ObGyn. EAS holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding with Romana A Nowak, PhD, which has no commercial activity. EAS has received royalties from UpToDate; has received fees for developing and/or presenting educational content from MED-IQ, Physicians’ Education Resource, Omnia Education, Omnicuris and WebMD; and serves as an unpaid advisor to The Fibroid Foundation and the unpaid treasurer of the International Gynecologic Society.

Disclosures: MDC has served as a consultant and editor for McGraw Hill and Elsevier.

Disclosures: XF declares that he has received research support from Otsuka, Roche, Bristol Myers Squibb, and Intra-Cellular Therapies. XF has served as a reviewer for various Substance Abuse and Mental Health Services Administration (SAMHSA) federal grant programs; he has also served on the Patient Centered Outcome Research Institute (PCORI) Advisory Panel on Healthcare Delivery and Disparities Research, as well as the American Psychiatric Association (APA) Scientific Program Committee. XF is a member of the APA Council on International Psychiatry and Global Health. XF holds a patent on “Combination Treatment for Neuropsychiatric Disorders” (USPTO Patent No. 11,331,319).

Disclosures: GAC declares that she has no competing interests.

Disclosures: KHC has been working with industry in the following: Amgen (Consultant, Grant/Research Support); AstraZeneca (Grant/Research Support); Bristol-Myers Squibb (BMS) (Consultant); Cabaletta Bio (Consultant, Grant/Research Support); Gilead (Grant/Research Support); GlaxoSmithKline (GSK) (Consultant, Grant/Research Support); Merck (Grant/Research Support).

Disclosures: CDS declares that he has been paid as a consultant to Lilac Therapeutics, Inc. CDS has research support paid to Duke University by Pfizer, Exelixis, Merck, BMS, and the Flume Catheter Company.

Disclosures: PS has received consulting fees from the following companies (serving as subject matter expert in the area of colonic perfusion assessment, anastomotic leak reduction initiatives, issues related to women in surgical practice): Ethicon, Safeheal, Olympus, Boehringer, Activ Surgical and Stryker.

SWS's academic medicine organization has received U.S. federal research grants.